Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 randomized open-label placebo-controlled study of BGC101 (EnEPC) for critical limb ischemia
MOH_2017-04-19_000323Phase 2Recruiting
- Sponsor
- BioGenCell
- Start
- Jul 2016
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of BGC101 in chronic limb-threatening ischemia (CLTI) and arteriosclerosis obliterans (2 arms), sponsored by BioGenCell. Started Jul 2016; status: recruiting.
02
Drugs
BGC101
03
Conditions
chronic limb-threatening ischemia (CLTI)arteriosclerosis obliterans
Beyond the preview
Go deeper on MOH_2017-04-19_000323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-04-19_000323.